{"id":78188,"date":"2026-09-02T15:26:22","date_gmt":"2026-09-02T07:26:22","guid":{"rendered":"https:\/\/flcube.com\/?p=78188"},"modified":"2026-09-02T15:26:23","modified_gmt":"2026-09-02T07:26:23","slug":"gsk-mrna-influenza-vaccine-candidate-shows-superior-immune-responses-in-phase-ii-versus-licensed-flu-shots","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=78188","title":{"rendered":"GSK mRNA Influenza Vaccine Candidate Shows Superior Immune Responses in Phase II Versus Licensed Flu Shots"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>GlaxoSmithKline Plc<\/strong> (GSK, <a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/GSK:NYSE\">NYSE: GSK<\/a>) announced positive Phase II clinical data for its <strong>mRNA<\/strong> seasonal <strong>influenza<\/strong> candidate vaccine. Compared to licensed standard-dose and high-dose inactivated flu vaccines, <strong>GSK<\/strong>&#8216;s candidate demonstrated higher immune responses against all tested flu strains in younger and older adults, respectively, and was generally well tolerated.<\/p>\n\n\n\n<h2 id=\"h-development-status\" class=\"wp-block-heading\">Development Status<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td>Sponsor<\/td><td><strong>GlaxoSmithKline Plc<\/strong> (NYSE: GSK)<\/td><\/tr><tr><td>Asset<\/td><td>Investigational <strong>mRNA<\/strong> seasonal <strong>influenza<\/strong> vaccine candidate<\/td><\/tr><tr><td>Stage<\/td><td>Phase II \u2013 positive topline data announced 01 Sep 2026<\/td><\/tr><tr><td>Comparators<\/td><td>Licensed standard-dose and high-dose inactivated flu vaccines<\/td><\/tr><tr><td>Regulatory status<\/td><td>Not approved anywhere in the world<\/td><\/tr><tr><td>Next steps<\/td><td>Continued development within <strong>GSK<\/strong>&#8216;s respiratory vaccine research program<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Modality:<\/strong> Investigational <strong>mRNA<\/strong> vaccine candidate targeting seasonal <strong>influenza<\/strong><\/li>\n\n\n\n<li><strong>Antigen design:<\/strong> Designed to target both hemagglutinin (HA) and neuraminidase (NA) \u2014 the two key surface glycoproteins of the influenza virus<\/li>\n\n\n\n<li><strong>Strategic context:<\/strong> Part of <strong>GSK<\/strong>&#8216;s respiratory vaccine research and ongoing efforts to explore new approaches to seasonal flu prevention<\/li>\n\n\n\n<li><strong>Differentiation potential:<\/strong> Dual HA\/NA targeting may broaden protection versus conventional inactivated vaccines focused primarily on HA<\/li>\n\n\n\n<li><strong>Regulatory status:<\/strong> The candidate <strong>mRNA influenza<\/strong> vaccine has not been approved anywhere in the world<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-evidence-phase-ii-topline\" class=\"wp-block-heading\">Clinical Evidence \u2013 Phase II (Topline)<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Comparator<\/th><th>Outcome<\/th><\/tr><\/thead><tbody><tr><td>Immune responses vs. tested flu strains<\/td><td>Standard-dose inactivated flu vaccine<\/td><td><strong>Higher immune responses in younger adults<\/strong><\/td><\/tr><tr><td>Immune responses vs. tested flu strains<\/td><td>High-dose inactivated flu vaccine<\/td><td><strong>Higher immune responses in older adults<\/strong><\/td><\/tr><tr><td>Tolerability<\/td><td>\u2014<\/td><td><strong>Generally well tolerated<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Across both age cohorts, <strong>GSK<\/strong>&#8216;s <strong>mRNA<\/strong> candidate outperformed the relevant licensed benchmarks \u2014 standard-dose in younger adults and high-dose in older adults \u2014 with responses observed against all tested flu strains, a profile that supports advancement into later-stage development.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Category disruption potential:<\/strong> Positive head-to-head immunogenicity versus licensed inactivated vaccines strengthens the case for <strong>mRNA<\/strong> technology in seasonal <strong>influenza<\/strong>, a market long dominated by egg- and cell-based platforms<\/li>\n\n\n\n<li><strong>Portfolio expansion:<\/strong> The program extends <strong>GSK<\/strong>&#8216;s respiratory vaccine franchise, complementing its established positions in flu and other preventive vaccines<\/li>\n\n\n\n<li><strong>Commercial stakes:<\/strong> Seasonal flu vaccination is a multi-billion-dollar global market; an <strong>mRNA<\/strong> candidate with superior immunogenicity could compete for share in both younger and older adult segments<\/li>\n\n\n\n<li><strong>Competitive race:<\/strong> The readout keeps <strong>GSK<\/strong> in the contest with other large pharma and biotech players pursuing <strong>mRNA influenza<\/strong> vaccines<\/li>\n\n\n\n<li><strong>Caution flag:<\/strong> The candidate is unapproved worldwide, and Phase II immunogenicity advantages must still translate into Phase III efficacy and regulatory success<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong> \u2013 This brief contains forward-looking statements regarding the clinical development, regulatory submissions, and commercial potential of GSK&#8217;s investigational mRNA influenza vaccine. Actual results may differ materially due to clinical, regulatory, and market risks. This content is for informational purposes only and does not constitute investment advice.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>GlaxoSmithKline Plc (GSK, NYSE: GSK) announced positive Phase II clinical data for its mRNA seasonal&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[17,278,184,63,914,12],"class_list":["post-78188","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-results","tag-glaxosmithkline","tag-gsk","tag-mrna","tag-nyse-gsk","tag-vaccine"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>GSK mRNA Influenza Vaccine Candidate Shows Superior Immune Responses in Phase II Versus Licensed Flu Shots - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"GlaxoSmithKline Plc (GSK, NYSE: GSK) announced positive Phase II clinical data for its mRNA seasonal influenza candidate vaccine. Compared to licensed standard-dose and high-dose inactivated flu vaccines, GSK&#039;s candidate demonstrated higher immune responses against all tested flu strains in younger and older adults, respectively, and was generally well tolerated.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=78188\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GSK mRNA Influenza Vaccine Candidate Shows Superior Immune Responses in Phase II Versus Licensed Flu Shots\" \/>\n<meta property=\"og:description\" content=\"GlaxoSmithKline Plc (GSK, NYSE: GSK) announced positive Phase II clinical data for its mRNA seasonal influenza candidate vaccine. Compared to licensed standard-dose and high-dose inactivated flu vaccines, GSK&#039;s candidate demonstrated higher immune responses against all tested flu strains in younger and older adults, respectively, and was generally well tolerated.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=78188\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-02T07:26:22+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-02T07:26:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78188#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78188\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"GSK mRNA Influenza Vaccine Candidate Shows Superior Immune Responses in Phase II Versus Licensed Flu Shots\",\"datePublished\":\"2026-09-02T07:26:22+00:00\",\"dateModified\":\"2026-09-02T07:26:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78188\"},\"wordCount\":459,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial results\",\"GlaxoSmithKline\",\"GSK\",\"mRNA\",\"NYSE: GSK\",\"Vaccine\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=78188#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78188\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=78188\",\"name\":\"GSK mRNA Influenza Vaccine Candidate Shows Superior Immune Responses in Phase II Versus Licensed Flu Shots - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-09-02T07:26:22+00:00\",\"dateModified\":\"2026-09-02T07:26:23+00:00\",\"description\":\"GlaxoSmithKline Plc (GSK, NYSE: GSK) announced positive Phase II clinical data for its mRNA seasonal influenza candidate vaccine. Compared to licensed standard-dose and high-dose inactivated flu vaccines, GSK's candidate demonstrated higher immune responses against all tested flu strains in younger and older adults, respectively, and was generally well tolerated.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78188#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=78188\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78188#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GSK mRNA Influenza Vaccine Candidate Shows Superior Immune Responses in Phase II Versus Licensed Flu Shots\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"GSK mRNA Influenza Vaccine Candidate Shows Superior Immune Responses in Phase II Versus Licensed Flu Shots - Insight, China&#039;s Pharmaceutical Industry","description":"GlaxoSmithKline Plc (GSK, NYSE: GSK) announced positive Phase II clinical data for its mRNA seasonal influenza candidate vaccine. Compared to licensed standard-dose and high-dose inactivated flu vaccines, GSK's candidate demonstrated higher immune responses against all tested flu strains in younger and older adults, respectively, and was generally well tolerated.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=78188","og_locale":"en_US","og_type":"article","og_title":"GSK mRNA Influenza Vaccine Candidate Shows Superior Immune Responses in Phase II Versus Licensed Flu Shots","og_description":"GlaxoSmithKline Plc (GSK, NYSE: GSK) announced positive Phase II clinical data for its mRNA seasonal influenza candidate vaccine. Compared to licensed standard-dose and high-dose inactivated flu vaccines, GSK's candidate demonstrated higher immune responses against all tested flu strains in younger and older adults, respectively, and was generally well tolerated.","og_url":"https:\/\/flcube.com\/?p=78188","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-09-02T07:26:22+00:00","article_modified_time":"2026-09-02T07:26:23+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=78188#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=78188"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"GSK mRNA Influenza Vaccine Candidate Shows Superior Immune Responses in Phase II Versus Licensed Flu Shots","datePublished":"2026-09-02T07:26:22+00:00","dateModified":"2026-09-02T07:26:23+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=78188"},"wordCount":459,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial results","GlaxoSmithKline","GSK","mRNA","NYSE: GSK","Vaccine"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=78188#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=78188","url":"https:\/\/flcube.com\/?p=78188","name":"GSK mRNA Influenza Vaccine Candidate Shows Superior Immune Responses in Phase II Versus Licensed Flu Shots - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-09-02T07:26:22+00:00","dateModified":"2026-09-02T07:26:23+00:00","description":"GlaxoSmithKline Plc (GSK, NYSE: GSK) announced positive Phase II clinical data for its mRNA seasonal influenza candidate vaccine. Compared to licensed standard-dose and high-dose inactivated flu vaccines, GSK's candidate demonstrated higher immune responses against all tested flu strains in younger and older adults, respectively, and was generally well tolerated.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=78188#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=78188"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=78188#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"GSK mRNA Influenza Vaccine Candidate Shows Superior Immune Responses in Phase II Versus Licensed Flu Shots"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/78188","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=78188"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/78188\/revisions"}],"predecessor-version":[{"id":78192,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/78188\/revisions\/78192"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=78188"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=78188"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=78188"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}